Webinar Accelerating Biologics Development to Medicines - Key Drivers of Success

This webinar was broadcasted LIVE on: Thursday, April 07, 2022

SPEAKER:

Dr. Sufia Karim, Director, Cell Line Development, Aragen Life Sciences
Dr. Sufia Karim is Director of Cell Line Development & Late-Stage R&D at Aragen Bioscience, Inc. She has more than 18 years’ experience in the biotech industry, including leading cell line development, cell culture, process development & optimization, and successful tech transfer. Dr. Karim previously worked with Boehringer Ingelheim and Amgen. She earned her MD from Sir Salimullah Medical College (Dhaka, Bangladesh) and her MS in molecular and microbiology from San Jose State University.

ABSTRACT:

The biopharmaceutical industry has made great strides in delivering cost-effective therapies to the market in the shortest timelines within regulatory guidelines. However, these advances are challenged by increasingly complex biologics formats and the subsequent additional analytical work for biologics development. In today’s highly competitive landscape, it is necessary for biotech and pharmaceutical companies to focus on core capabilities while relying on a network of collaborators, vendors and regulatory experts to fill gaps.

Key to biopharmaceutical R&D is selecting contract research organizations (CROs) that share a company’s goals of safety, quality, speed and low cost. At the same time, it is important to evaluate multiple cell line development (CLD) platforms to determine which platform will produce optimal titers.

Join this webinar to learn strategies to shorten timelines while minimizing safety and regulatory risks for biologics development. The featured speaker will also detail CLD platform options and how testing across multiple platforms simultaneously can help reduce timelines and reduce risks.

#Biologics #Biosimilars #Biobetters #CellLineDevelopment #BiologicsDevelopment #AragenBiologics